Heather Wakelee

Heather A. Wakelee is a professor of oncology at Stanford University Medical Center. Her research focuses on lung cancer.

Wakelee received a Bachelor's degree in molecular biology from Princeton University in 1992 and MD from Johns Hopkins University in 1996. She is a member of Alpha Omega Alpha. She served as an intern, as a resident in internal medicine, and as a fellow in oncology at Stanford from 1996 to 2003. She was appointed as a staff physician in 2003.

Wakelee is an author on over 180 papers related to cancer research. In 2003, she was given a Merit Award from the American Society of Clinical Oncology.

She is the lead investigator on the ECOG-ARIN clinical trials group at Stanford, and was given a Young Investigator Award from ECOG-ARIN in 2015. She serves on the board of directors of the International Association for the Study of Lung Cancer. Provided by Wikipedia
Showing 1 - 7 results of 7 for search 'Heather Wakelee', query time: 0.03s Refine Results
  1. 1
    Chemotherapy Definitions and Policies for Thymic Malignancies

    Chemotherapy Definitions and Policies for Thymic Malignancies by Nicolas Girard, Rohit Lal, Heather Wakelee, Gregory J. Riely, Patrick J. Loehrer

    Published 2014-02-01
    Get full text
    Article
  2. 2
    Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma

    Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US onco... by Alexandra Drakaki, Preet K Dhillon, Heather Wakelee, Stephen Y Chui, Jinjoo Shim, Matthew Kent, Viraj Degaonkar, Tien Hoang, Virginia McNally, Patricia Luhn, Ralf Gutzmer

    Published 2020-01-01
    Get full text
    Article
  3. 3
    Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry

    Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry by Loukia G. Karacosta, Danny Pancirer, Jordan S. Preiss, Jalen A. Benson, Winston Trope, Joseph B. Shrager, Arthur Wai Sung, Joel W. Neal, Sean C. Bendall, Heather Wakelee, Sylvia K. Plevritis

    Published 2023-12-01
    Get full text
    Article
  4. 4
    Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors

    Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors by Thomas Yang Sun, MD, MHS, Brandon Nguyen, BA, Simon B. Chen, MD, Yasodha Natkunam, MD, PhD, Sukhmani Padda, MD, Matt van de Rijn, MD, Robert West, MD, PhD, Joel W. Neal, MD, PhD, Heather Wakelee, MD, Jonathan W. Riess, MD, MS

    Published 2023-04-01
    Get full text
    Article
  5. 5
    Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

    Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III I... by Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch

    Published 2023-10-01
    Get full text
    Article
  6. 6
    A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

    A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With R... by Kathryn E. Beckermann, MD, PhD, Christine M. Bestvina, MD, Badi El Osta, MD, Rachel E. Sanborn, MD, Hossein Borghaei, MD, Philip Edward Lammers, MD, MSCI, Giovanni Selvaggi, MD, Jennifer G. Whisenant, PhD, Ellen Heimann-Nichols, MBA, Lynne Berry, PhD, Chih-Yuan Hsu, PhD, Yu Shyr, PhD, Leora Horn, MD, MSc, MHPE, Heather Wakelee, MD, FASCO

    Published 2024-02-01
    Get full text
    Article
  7. 7
    Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

    Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis by Christine M. Bestvina, MD, Jennifer G. Whisenant, PhD, Valter Torri, MD, Alessio Cortellini, MD, Heather Wakelee, MD, Solange Peters, MD, PhD, Elisa Roca, MD, PhD, Alessandro De Toma, MD, Fred R. Hirsch, MD, Hirva Mamdani, MD, Balazs Halmos, MD, Oscar Arrieta, MD, Anne-Cecile Metivier, MD, Mary J. Fidler, MD, Jacobo Rogado, MD, Carolyn J. Presley, MD, MHS, Celine Mascaux, MD, Carlo Genova, MD, PhD, Juan Bautista Blaquier, MD, Alfredo Addeo, MD, Giovanna Finocchiaro, MD, Hina Khan, MD, Julien Mazieres, MD, PhD, Floriana Morgillo, MD, PhD, Jair Bar, MD, Avinash Aujayeb, MBBS, Giannis Mountzios, MD, PhD, Vieri Scotti, MD, Federica Grosso, MD, Erica Geraedts, MD, Ardak N. Zhumagaliyeva, MD, PhD, Leora Horn, MD, Marina Chiara Garassino, MD, Javier Baena, MD

    Published 2022-08-01
    Get full text
    Article

Search Tools: